{
    "guideline_id": "2024CSCO非小细胞肺癌诊疗指南- .txt",
    "cancer_info": {
        "cancer_name": "Non-Small Cell Lung Cancer"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Early-stage NSCLC (IA-IB)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Surgical resection: anatomic lobectomy with lymph node dissection",
            "treatment_line": "Primary",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Early-stage NSCLC (IIA-IIB)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Surgery plus platinum-based adjuvant chemotherapy",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Resectable stage IIIA-IIIB NSCLC",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Neoadjuvant or adjuvant therapy: Toripalimab plus platinum-based chemotherapy (for immunotherapy) or Osimertinib (for EGFR mutation-positive)",
            "treatment_line": "Neoadjuvant/Adjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "EGFR",
                    "status": "Positive",
                    "testing_guidance": "Test for EGFR mutations to guide Osimertinib use"
                },
                {
                    "biomarker_name": "PD-L1",
                    "status": "Any",
                    "testing_guidance": "Test PD-L1 expression to guide immunotherapy selection"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Unresectable stage IIIA-IIIB/IIIC NSCLC",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Radical concurrent chemoradiotherapy (cisplatin plus etoposide or pemetrexed), followed by consolidation therapy with Durvalumab or Sugemalimab",
            "treatment_line": "Primary",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "IV stage NSCLC with EGFR mutation",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line: Osimertinib or Befotertinib; For T790M-positive: Befotertinib; For exon 20 insertion: Amivantamab plus chemotherapy (third-line) or Surufatinib (later-line)",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "EGFR",
                    "status": "Sensitive mutation (e.g., 19del, L858R)",
                    "testing_guidance": "Mandatory testing for all IV stage non-squamous NSCLC; use tissue NGS or ctDNA if tissue insufficient"
                },
                {
                    "biomarker_name": "T790M",
                    "status": "Detected after resistance",
                    "testing_guidance": "Re-biopsy upon EGFR-TKI resistance to identify T790M mutation"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "IV stage NSCLC with ALK fusion",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line: Alectinib, Brigatinib, Lorlatinib, or Iluacitinib; Later-line: Iluacitinib after Crizotinib resistance",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "ALK",
                    "status": "Fusion-positive",
                    "testing_guidance": "Mandatory testing for all IV stage non-squamous NSCLC; use NGS for detection"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "IV stage NSCLC with ROS1 fusion",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line: Entrectinib or Repotrectinib",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "ROS1",
                    "status": "Fusion-positive",
                    "testing_guidance": "Mandatory testing for all IV stage NSCLC; use NGS"
                }
            ],
            "recommendation_level": "Level III Recommendation",
            "evidence_level": "Evidence 3"
        },
        {
            "clinical_context": "IV stage NSCLC with other driver mutations (e.g., RET fusion, MET exon 14 skipping)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line for RET fusion: Selpercatinib or Pralsetinib; Later-line for MET exon 14 skipping: Glumetinib, Tepotinib, or Bometinib",
            "treatment_line": "First-line or Later-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "RET",
                    "status": "Fusion-positive",
                    "testing_guidance": "Test for RET fusions; NGS recommended"
                },
                {
                    "biomarker_name": "MET",
                    "status": "Exon 14 skipping mutation",
                    "testing_guidance": "Test for MET mutations; tissue biopsy preferred"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "IV stage NSCLC without driver mutations (non-squamous)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line: Pembrolizumab monotherapy if PD-L1 ≥50%; or platinum-based chemotherapy plus immunotherapy (e.g., Pembrolizumab, Camrelizumab, Sintilimab) if PD-L1 <50%",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PD-L1",
                    "status": "Any",
                    "testing_guidance": "Mandatory testing for PD-L1 expression (TPS or TC/IC score) using approved IHC methods; threshold: TPS ≥50% for monotherapy"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "IV stage NSCLC without driver mutations (squamous)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line: Pembrolizumab if PD-L1 ≥50%; or platinum-based chemotherapy plus immunotherapy",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PD-L1",
                    "status": "Any",
                    "testing_guidance": "Test PD-L1 expression to guide treatment choice"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Isolated metastases (e.g., brain, adrenal, bone)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Surgery or stereotactic radiotherapy plus systemic therapy; for bone metastases: local radiotherapy plus bisphosphonates",
            "treatment_line": "Primary",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Predicts efficacy of targeted therapy and immunotherapy; e.g., EGFR mutations indicate response to EGFR-TKIs (ORR 60-80%), ALK fusions predict benefit from ALK inhibitors (PFS up to 34.8 months), PD-L1 high expression correlates with improved OS with immunotherapy. Biomarker status guides personalized treatment selection and resistance management."
    },
    "tcm_recommendations": []
}